YBX1 and chronic myelogenous leukemia, BCR-ABL1 positive: P22077, a dual inhibitor of USP7/USP47 [77], overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia through inhibiting its novel substrate Y-box binding protein 1 (YB-1) deubiquitination and suppresses DNA damage repair [78].